Article Sidebar
Views pdf: 0
HISTOPATHOLOGICAL FEATURES, THE ASSOCIATION BETWEEN EGFR GENE MUTATIONS AND PD-L1 MARKER EXPRESSION IN LUNG ADENOCARCINOMA PATIENTS
Main Article Content
Abstract
Objective: To describe the histopathological characteristics of lung adenocarcinoma based on the 2015 World Health Organization classification. Determine the frequency of EGFR mutations as well as their association with PD-L1 expression in patients with lung adenocarcinoma Methods: Cross-sectional descriptive study, conducted on 107 patients who had surgery and were diagnosed with lung adenocarcinoma at National Lung Hospital. Results: The proportion of patients with high PD-L1 expression was 10.3%. High PD-L1 expression was associated with histological subtypes, predominantly observed in high-grade patterns such as solid and micropapillary. The frequency of EGFR mutations was 57.9%, significantly associated with female gender and non-smoking status. No correlation was found between EGFR mutations status and PD-L1 expression. Conclusion: High PD-L1 expression (≥50%) was predominantly detected in high-grade histological subtypes, solid and micropapillary patterns. EGFR mutations were identified in 57.9% of resected cases, most frequently in women and non-smokers. The most common mutation types were exon 19 deletions (Del19) and exon 21 L858R substitutions. However, statistical analysis revealed no significant association between PD-L1 expression and EGFR mutation status
Article Details
Keywords
adenocarcinoma in lung, EGFR mutations, Del exon 19, L858R exon 21, PD-L1 expression, surgical specimens.
References
2. A Y, N M, Gj R, Cs S, Wl G, Mg K, et al. Impact of proposed IASLC/ATS/ERS classification of lung adenocarcinoma: prognostic subgroups and implications for further revision of staging based on analysis of 514 stage I cases. Mod Pathol Off J U S Can Acad Pathol Inc 2011;24. https://doi.org/10.1038/modpathol.2010.232.
3. Jhala H, Harling L, Rodrigo A, Nonaka D, Mclean E, Ng W, et al. Clinicopathological predictors of survival in resected primary lung adenocarcinoma. J Clin Pathol 2022;75:310–5. https://doi.org/10.1136/jclinpath-2021-207388.
4. Koh J, Go H, Keam B, Kim M-Y, Nam SJ, Kim TM, et al. Clinicopathologic analysis of programmed cell death-1 and programmed cell death-ligand 1 and 2 expressions in pulmonary adenocarcinoma: comparison with histology and driver oncogenic alteration status. Mod Pathol 2015;28: 1154–66. https://doi.org/10.1038/ modpathol.2015.63.
5. Driver BR, Miller RA, Miller T, Deavers M, Gorman B, Mody D, et al. Programmed Death Ligand-1 (PD-L1) Expression in Either Tumor Cells or Tumor-Infiltrating Immune Cells Correlates With Solid and High-Grade Lung Adenocarcinomas. Arch Pathol Lab Med 2017;141:1529–32. https://doi.org/10.5858/arpa. 2017-0028-OA.
6. Mok TS, Wu Y-L, Thongprasert S, Yang C-H, Chu D-T, Saijo N, et al. Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma. N Engl J Med 2009;361:947–57. https://doi.org/10.1056/NEJMoa0810699.
7. Yotsukura M, Yasuda H, Shigenobu T, Kaseda K, Masai K, Hayashi Y, et al. Clinical and pathological characteristics of EGFR mutation in operable early-stage lung adenocarcinoma. Lung Cancer Amst Neth 2017;109:45–51. https://doi.org/10.1016/j.lungcan.2017.04.014.
8. Soo RA, Lim SM, Syn NL, Teng R, Soong R, Mok TSK, et al. Immune checkpoint inhibitors in epidermal growth factor receptor mutant non-small cell lung cancer: Current controversies and future directions. Lung Cancer Amst Neth 2018;115:12–20. https://doi.org/ 10.1016/ j.lungcan.2017.11.009.